Biological Sciences Tech Calls | Innoget

Find Tech Calls in Biological Sciences, Neurology, Nanotechnology, Biochemistry, Microbiology, Bionics, Ehealth and more posted by leading companies on Innoget

  1. Home
  2. Technology Calls
  3. Biological Sciences
Open Science has turned to be one of the key resources for Industry and financial development. Thanks to Open Innovation platforms and Open Innovation communities, collaboration in research and development between businesses and outer groups of specialists, for instance, Universities, research organizations, startups and scientists is thriving innovation and new product development in the sectors of molecular biology, ehealth, biological sciences, genome research, gene expression, bioplastics, biophysics and bacteriology, among many other areas of research. Innoget, the largest open innovation community for technology and knowledge transfer, offers a unique way to directly interact with large enterprises, SMEs and other industry players who are looking for novel technologies. Find below the full list of Technology Calls related to Biological Sciences.

Organization from European Union posted this Technology Call

We are seeking for molecules/compounds/materials which are chemically composed of two opposite parts (see Fig.). The first part of such molecules has a hyperbranched/dendrimer-like/fork shape. The second part (which is geometrically opposit to the first) is a moiety which will favour attachement. The attachment on the skin or hair surface could be generated by adhesion, covalent bonding, electrostatic attachment etc. For instance such latter moieity could react with free amines present on the hair fibers (more attachment points on the skin and hair could be considered, e.g. hydroxyl groups). Lactone groups are an example reported in literature of a reactive moiety which upon heat application can bound to the free amine of the hair. Once bounded to the skin/hair such molecules will work as molecular spacers. The molecules need to be neutrally charged, rigid, branched and have a low particle density (number of atoms in a physical volume). They will therefore decrease the interaction (e.g. Van der Walls attactions) between external particles (such as sand or dust) and the functionalized surface. Example: N-Glycans are an example of such molecular spacers and an example of desired geometrical structure. Glycan with 5 Mannose units for instance will occupy a Volume of 2.25 x 1.65 x 1.24nm with 162 atoms, which lead to a particle density of 35 x 10(^27) atoms/m^3. Such lower particle density will lead to a reduction of the Hamaker-interaction coeffiecint between the funcitonalized surface and an approaching particle. Such molecule will therefore lead to a decrease of the friction coefficient and adhesion forces.
Seeking hyperbranched, non charged, short molecules/dendrimers able to be coupled to keratinous surfaces

Juli Ramon posted this Technology Call
Account Manager at GCCIR

As a participant of the upcoming symposium “GCCIR Matchmaking Symposium” organized by the GCCIR and Innoget next 19 November 2018 in Barcelona (Spain), the company Innovative Trauma Care Inc. (iTraumaCare) is seeking European partners to meet at the Barcelona event to jointly develop R&D projects. As an alternative to hemostatic bandages, iTraumaCare is developing a medical hemostatic glove adapted to tightly conform over a donned medical barrier glove. The External Hemostatic Gloves for Hemorrhage Control device is designed for use in a field (or surgical) environment that provides a means to combine the advantages of applying a hemostatic dressing with the simplicity of applying a traditional manual pressure via a gloved hand. iTraumaCare is specifically interested in collaborating with partners in the following areas: I. To enable the hemostasis function of the glove, a protected hemostatic agent is required. Being that the IP and regulatory burden for hemostatic agents is quite involved, it would be of interest for iTraumaCare to have a partner that has previously worked with, has regulatory clearance with and has IP associated with one or more hemostatic agents. II. As a complement to the hemostasis function of the glove material, additional pharmacologically and biologically active agents could be absorbed to the glove, including but not limited to, antifibrinolytics, styptics, antibacterial agents, antimicrobial agents, analgesic and anaesthetic agents for treatment. A company that has interest with, regulatory clearance with and IP protection of such areas would be of interest. Additional regulatory clearance would be required for the different formulations with different indications for use, so partners with regulatory cleared chemistry would be preferred. As a product class, these combination products could lead to multiple and varied products for sale. III. To create a hemostatic glove, raw materials manufactures will be required. Manufacturers with IP in development for unique manufacturing of hemostatic fibres, acting like a tightly conforming hemostatic bandage, the actions of the surgeon’s physician’s, warfighter’s or medic’s hands and fingers applying manual pressure will also accelerate hemostasis chemically. Material manufacturers for hemostatic gloves can be used similar to most of the current sources materials for hemostatic bandages such as packing into wounds for contact hemostasis, wherein the glove can be removed from the caregiver’s hands and temporarily inserted into the wound to temporize blood loss. In case you are interested in meeting iTraumaCare at the Barcelona event to discuss a potential collaboration, please register for free to the symposium through the orange button provided above.
Seeking European partners to develop a novel medical hemostatic glove to tightly conform over a donned medical barrier glove